Nektar Therapeutics is a leading biopharma company headquartered in San Francisco. The company is listed in the top 50 big biotech list by Current Partnering. The company is a world leader in polymer chemistry which involves the design of drugs with optimized drug pharmacology.
Nektar Therapeutics announced only about 3 partnering / licensing deals since 2009. The company has had several strategic partnerships in the past for compounds, reagents and technology with companies like AstraZeneca, Bayer, Pfizer, Roche, etc
The company has not entered into any partnerships recently. The company is developing a diverse and deep pipeline of products covering carious therapeutic disciplines some of which are still in the early stages of development. This could be a potential lure for partners to enter into a strategic collaboration with the company.
The following figure shows the level of Nektar Therapeutics partnering deal announcements since 2009.
Figure 1: Nektar Therapeutics partnering deals 2009-2014
Source: Current Agreements, 2014
The following table provides an overview of the partnering deals announced by Nektar Therapeutics based on specific therapy area disclosed.
Figure 2: Nektar Therapeutics partnering deals by therapy area 2009-2014
Source: Current Agreements, 2014
Further analysis of these deals shows that Nektar Therapeutics has a preference for licensing and supply deals.
The following table provides an overview of the partnering deals announced by Nektar Therapeutics based on deal type disclosed.
Figure 3: Nektar Therapeutics partnering deals by deal type 2009-2014
Source: Current Agreements, 2014
Nektar Therapeutics is constantly searching for partners to co develop and jointly discover next generation of successful drugs to meet critical unmet needs.
The following table provides an overview of the partnering deals announced by Nektar Therapeutics based on stage of development at signature.
Figure 4: Nektar Therapeutics partnering by stage of development 2009-2014
Source: Current Agreements, 2014
Nektar Therapeutics has entered into high value licensing deals- Eg: In Sep 2009, AstraZeneca and Nektar Therapeutics entered into a licensing agreement for compounds NKTR-118 and NKTR-119 which were compounds developed against pain and constipation. The deal was valued at $735 million that included upfront and milestone payments and was also promised double digit royalty rates on net sale of the compounds.
As an emerging big biotech company, Nektar Therapeutics is working towards being a market leader for novel therapeutics with advanced polymer conjugate technologies.
Nektar Therapeutics partnering at Current Agreements
View all partnering deals for Nektar Therapeutics: 2014 | 2013 | 2012 | 2011 | 2010 | 2009
Full details on each deal can be found at CurrentAgreements (subscription required)
Or purchase report: Partnering Agreements with Nektar Therapeutics 2009-2014
More
Summary profile for Nektar Therapeutics
Partnering interests for Nektar Therapeutics
No M&A activity for Nektar Therapeutics
Available reports from Current Partnering
Report: Top 50 Big Pharma Partnering and M&A Deals and Alliances
Report: Top 50 Big Biotech Partnering and M&A Deals and Alliances
Available resources for deal coverage for Nektar Therapeutics
Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more
Read: more on Nektar Therapeutics company profile, recent partnering, M&A and financing news and articles
Related
View: CP Insight’s Partnering Scorecard – view top life science partnering deals by value
View: CP Insight’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now
Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk
Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter
